ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 803.7 USD | +2.63% |
|
+5.20% | +37.87% |
| 06:00pm | Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson... |  |
| 04:48pm | Eli Lilly: conclusive trial in Crohn's disease | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
783.2
USD
Average target price
850.4
USD
Spread / Average Target
+8.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.87% | 705B | |
| +32.82% | 583B | |
| -3.72% | 364B | |
| +19.83% | 332B | |
| +4.89% | 291B | |
| +16.64% | 238B | |
| -4.13% | 210B | |
| +10.63% | 209B | |
| +8.78% | 169B | |
| -0.99% | 162B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Sector Update: Health Care Stocks Mostly Rising Tuesday Afternoon
